drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00434 | DB00450 | 13 | 78 | [
"DDInter459",
"DDInter603"
] | Cyproheptadine | Droperidol | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Moderate | 1 | [
[
[
13,
24,
78
]
],
[
[
13,
24,
1300
],
[
1300,
40,
78
]
],
[
[
13,
24,
1568
],
[
1568,
1,
78
]
],
[
[
13,
6,
4228
],
[
4228,
45,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droperidol"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Haloperidol"
],... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Haloperidol and Haloperidol (Compound) resembles Droperidol (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Pimozide and Pimozide (Compound) resembles Droperidol (Comp... |
DB00059 | DB05528 | 1,560 | 1,070 | [
"DDInter1404",
"DDInter1228"
] | Pegaspargase | Mipomersen | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Major | 2 | [
[
[
1560,
25,
1070
]
],
[
[
1560,
24,
292
],
[
292,
64,
1070
]
],
[
[
1560,
24,
1512
],
[
1512,
25,
1070
]
],
[
[
1560,
25,
581
],
[
581,
... | [
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
],
[
"Regor... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may ... |
DB00363 | DB06772 | 695 | 310 | [
"DDInter419",
"DDInter259"
] | Clozapine | Cabazitaxel | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Major | 2 | [
[
[
695,
25,
310
]
],
[
[
695,
25,
973
],
[
973,
24,
310
]
],
[
[
695,
6,
4973
],
[
4973,
45,
310
]
],
[
[
695,
25,
868
],
[
868,
63... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} ma... | Clozapine may lead to a major life threatening interaction when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Clozapine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Cabazitaxel (Compound)
Clozapine may lead to a major life ... |
DB00524 | DB00959 | 811 | 1,486 | [
"DDInter1199",
"DDInter1191"
] | Metolazone | Methylprednisolone | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
811,
24,
1486
]
],
[
[
811,
24,
175
],
[
175,
40,
1486
]
],
[
[
811,
24,
167
],
[
167,
1,
1486
]
],
[
[
811,
63,
251
],
[
251,
1... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
... | Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles ... |
DB08870 | DB09570 | 850 | 1,480 | [
"DDInter228",
"DDInter1002"
] | Brentuximab vedotin | Ixazomib | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
850,
24,
1480
]
],
[
[
850,
24,
987
],
[
987,
63,
1480
]
],
[
[
850,
63,
440
],
[
440,
24,
1480
]
],
[
[
850,
24,
98
],
[
98,
24... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio chol... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Brentuximab vedotin may cause a... |
DB00863 | DB08827 | 1,194 | 990 | [
"DDInter1568",
"DDInter1085"
] | Ranitidine | Lomitapide | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Moderate | 1 | [
[
[
1194,
24,
990
]
],
[
[
1194,
6,
8374
],
[
8374,
45,
990
]
],
[
[
1194,
21,
28701
],
[
28701,
60,
990
]
],
[
[
1194,
24,
1476
],
[
1476... | [
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Ranitidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Ranitidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Ranitidine (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Lomitapide (Compound)
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Br... |
DB06589 | DB09039 | 1,250 | 1,670 | [
"DDInter1400",
"DDInter629"
] | Pazopanib | Eliglustat | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
1250,
24,
1670
]
],
[
[
1250,
62,
479
],
[
479,
23,
1670
]
],
[
[
1250,
23,
1135
],
[
1135,
62,
1670
]
],
[
[
1250,
63,
1164
],
[
1164... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Pazopanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"... | Pazopanib may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Pazopanib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cau... |
DB00261 | DB04868 | 702 | 478 | [
"DDInter93",
"DDInter1293"
] | Anagrelide | Nilotinib | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
702,
25,
478
]
],
[
[
702,
25,
1468
],
[
1468,
63,
478
]
],
[
[
702,
5,
11555
],
[
11555,
44,
478
]
],
[
[
702,
7,
7095
],
[
7095,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may ... | Anagrelide may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Anagrelide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Nilotinib (Compound)
Anag... |
DB08883 | DB11130 | 1,597 | 407 | [
"DDInter1428",
"DDInter1344"
] | Perampanel | Opium | Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning ... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1597,
24,
407
]
],
[
[
1597,
63,
662
],
[
662,
24,
407
]
],
[
[
1597,
24,
1609
],
[
1609,
63,
407
]
],
[
[
1597,
63,
662
],
[
662,
... | [
[
[
"Perampanel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Perampanel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Perampanel may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Perampanel may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pe... |
DB00074 | DB08895 | 1,309 | 976 | [
"DDInter166",
"DDInter1825"
] | Basiliximab | Tofacitinib | A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermenta... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
1309,
25,
976
]
],
[
[
1309,
23,
1193
],
[
1193,
62,
976
]
],
[
[
1309,
23,
1461
],
[
1461,
23,
976
]
],
[
[
1309,
24,
200
],
[
200,
... | [
[
[
"Basiliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Basiliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc ... | Basiliximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Basiliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vi... |
DB06335 | DB08886 | 761 | 637 | [
"DDInter1646",
"DDInter126"
] | Saxagliptin | Asparaginase Erwinia chrysanthemi | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
761,
24,
637
]
],
[
[
761,
63,
392
],
[
392,
24,
637
]
],
[
[
761,
24,
850
],
[
850,
24,
637
]
],
[
[
761,
24,
159
],
[
159,
63,... | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"La... | Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01324 | DB04843 | 178 | 1,511 | [
"DDInter1490",
"DDInter1149"
] | Polythiazide | Mepenzolate | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Minor | 0 | [
[
[
178,
23,
1511
]
],
[
[
178,
62,
1192
],
[
1192,
24,
1511
]
],
[
[
178,
21,
28898
],
[
28898,
60,
1511
]
],
[
[
178,
1,
674
],
[
674,
... | [
[
[
"Polythiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mepenzolate"
]
],
[
[
"Polythiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glycopyrronium"
],
... | Polythiazide may cause a minor interaction that can limit clinical effects when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Polythiazide (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by M... |
DB00489 | DB14568 | 17 | 982 | [
"DDInter1704",
"DDInter1000"
] | Sotalol | Ivosidenib | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
17,
25,
982
]
],
[
[
17,
23,
112
],
[
112,
23,
982
]
],
[
[
17,
63,
608
],
[
608,
23,
982
]
],
[
[
17,
24,
976
],
[
976,
24,
... | [
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Sotalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",... | Sotalol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine m... |
DB00376 | DB11130 | 1,105 | 407 | [
"DDInter1870",
"DDInter1344"
] | Trihexyphenidyl | Opium | Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is n... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1105,
24,
407
]
],
[
[
1105,
24,
662
],
[
662,
24,
407
]
],
[
[
1105,
40,
456
],
[
456,
24,
407
]
],
[
[
1105,
1,
1386
],
[
1386,
... | [
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
... | Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Trihexyphenidyl (Compound) resembles Biperiden (Compound) and Biperiden may cause a moderate interaction t... |
DB00673 | DB12941 | 723 | 466 | [
"DDInter112",
"DDInter481"
] | Aprepitant | Darolutamide | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Minor | 0 | [
[
[
723,
23,
466
]
],
[
[
723,
63,
1622
],
[
1622,
23,
466
]
],
[
[
723,
24,
34
],
[
34,
23,
466
]
],
[
[
723,
1,
875
],
[
875,
23,
... | [
[
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and... |
DB00530 | DB15093 | 1,195 | 1,654 | [
"DDInter667",
"DDInter1698"
] | Erlotinib | Somapacitan | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
1195,
24,
1654
]
],
[
[
1195,
64,
1215
],
[
1215,
24,
1654
]
],
[
[
1195,
24,
351
],
[
351,
24,
1654
]
],
[
[
1195,
1,
883
],
[
883,
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Erlotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lansoprazole"
],
[
"Lansopraz... | Erlotinib may lead to a major life threatening interaction when taken with Lansoprazole and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cau... |
DB06016 | DB12500 | 1,508 | 283 | [
"DDInter300",
"DDInter714"
] | Cariprazine | Fedratinib | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1508,
24,
283
]
],
[
[
1508,
24,
351
],
[
351,
23,
283
]
],
[
[
1508,
63,
1419
],
[
1419,
24,
283
]
],
[
[
1508,
24,
761
],
[
761,
... | [
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib... |
DB00814 | DB12364 | 1,171 | 1,421 | [
"DDInter1143",
"DDInter200"
] | Meloxicam | Betrixaban | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
1171,
25,
1421
]
],
[
[
1171,
24,
1017
],
[
1017,
24,
1421
]
],
[
[
1171,
63,
305
],
[
305,
24,
1421
]
],
[
[
1171,
24,
714
],
[
714,
... | [
[
[
"Meloxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",... | Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichi... |
DB00365 | DB00877 | 839 | 629 | [
"DDInter842",
"DDInter1678"
] | Grepafloxacin | Sirolimus | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
839,
24,
629
]
],
[
[
839,
24,
1114
],
[
1114,
62,
629
]
],
[
[
839,
24,
1215
],
[
1215,
24,
629
]
],
[
[
839,
24,
1476
],
[
1476,
... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc sulfate"
],
... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Sirolimus
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole a... |
DB06273 | DB06688 | 980 | 1,430 | [
"DDInter1824",
"DDInter1677"
] | Tocilizumab | Sipuleucel-T | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
980,
24,
1430
]
],
[
[
980,
25,
676
],
[
676,
63,
1430
]
],
[
[
980,
64,
1531
],
[
1531,
24,
1430
]
],
[
[
980,
24,
310
],
[
310,
... | [
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Tocilizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upad... | Tocilizumab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Tocilizumab may lead to a major life threatening interaction when taken with Canakinumab and Canakinumab may cause a mod... |
DB01403 | DB09488 | 9 | 103 | [
"DDInter1175",
"DDInter23"
] | Methotrimeprazine | Acrivastine | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
9,
24,
103
]
],
[
[
9,
63,
85
],
[
85,
24,
103
]
],
[
[
9,
1,
146
],
[
146,
24,
103
]
],
[
[
9,
40,
1630
],
[
1630,
24,
10... | [
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
... | Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Methotrimeprazine (Compound) resembles Propiomazine (Compound) and Propiomazine may cause a moderate interac... |
DB00624 | DB01234 | 1,561 | 1,220 | [
"DDInter1775",
"DDInter513"
] | Testosterone | Dexamethasone | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual charact... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
1561,
24,
1220
]
],
[
[
1561,
24,
870
],
[
870,
1,
1220
]
],
[
[
1561,
63,
175
],
[
175,
40,
1220
]
],
[
[
1561,
24,
617
],
[
617,
... | [
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
... | Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles... |
DB01067 | DB11901 | 959 | 913 | [
"DDInter826",
"DDInter107"
] | Glipizide | Apalutamide | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
959,
24,
913
]
],
[
[
959,
63,
1247
],
[
1247,
23,
913
]
],
[
[
959,
24,
1060
],
[
1060,
62,
913
]
],
[
[
959,
64,
600
],
[
600,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
... | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab v... |
DB00976 | DB08870 | 1,056 | 850 | [
"DDInter1758",
"DDInter228"
] | Telithromycin | Brentuximab vedotin | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1056,
24,
850
]
],
[
[
1056,
1,
1570
],
[
1570,
24,
850
]
],
[
[
1056,
63,
896
],
[
896,
24,
850
]
],
[
[
1056,
64,
134
],
[
134,
... | [
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Telithromycin",
"{u} (Compound) resembles {v} (Compound)",
"Azithromycin"
],
[
"Azithromycin",
"{u} ... | Telithromycin (Compound) resembles Azithromycin (Compound) and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate inter... |
DB00204 | DB12245 | 228 | 823 | [
"DDInter580",
"DDInter1863"
] | Dofetilide | Triclabendazole | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Major | 2 | [
[
[
228,
25,
823
]
],
[
[
228,
23,
112
],
[
112,
23,
823
]
],
[
[
228,
25,
1010
],
[
1010,
24,
823
]
],
[
[
228,
24,
28
],
[
28,
24,... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Dofetilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Dofetilide may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine may... |
DB00731 | DB01037 | 1,144 | 1,161 | [
"DDInter1269",
"DDInter1653"
] | Nateglinide | Selegiline | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual... | Moderate | 1 | [
[
[
1144,
24,
1161
]
],
[
[
1144,
24,
551
],
[
551,
1,
1161
]
],
[
[
1144,
35,
1529
],
[
1529,
1,
1161
]
],
[
[
1144,
24,
280
],
[
280,
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
[
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Selegiline (Compound)
Nateglinide (Compound) resembles Metamfetamine (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Metam... |
DB00005 | DB11714 | 1,057 | 1,316 | [
"DDInter687",
"DDInter610"
] | Etanercept | Durvalumab | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote... | Major | 2 | [
[
[
1057,
25,
1316
]
],
[
[
1057,
23,
1461
],
[
1461,
23,
1316
]
],
[
[
1057,
25,
167
],
[
167,
24,
1316
]
],
[
[
1057,
24,
1136
],
[
1136... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Durvalumab"
]
],
[
[
"Etanercept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Etanercept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Durvalumab
Etanercept may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone may caus... |
DB00030 | DB00819 | 1,685 | 471 | [
"DDInter934",
"DDInter15"
] | Insulin human | Acetazolamide | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Moderate | 1 | [
[
[
1685,
24,
471
]
],
[
[
1685,
24,
997
],
[
997,
40,
471
]
],
[
[
1685,
24,
1572
],
[
1572,
23,
471
]
],
[
[
1685,
24,
1669
],
[
1669,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide and Methazolamide (Compound) resembles Acetazolamide (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline may cause a minor in... |
DB00201 | DB00740 | 1,684 | 424 | [
"DDInter263",
"DDInter1596"
] | Caffeine | Riluzole | Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to [Theophylline] and [Theobromine].[A187691,L9851] It can be sourced from coffee beans, but ... | A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi. | Minor | 0 | [
[
[
1684,
23,
424
]
],
[
[
1684,
6,
9842
],
[
9842,
45,
424
]
],
[
[
1684,
21,
29221
],
[
29221,
60,
424
]
],
[
[
1684,
24,
1031
],
[
1031... | [
[
[
"Caffeine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Riluzole"
]
],
[
[
"Caffeine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A1"
],
[
"CYP1A1",
"{u} (Gene) is bound by {v} (Compound)",
"... | Caffeine (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Riluzole (Compound)
Caffeine (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Riluzole (Compound)
Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophyl... |
DB00284 | DB00827 | 1,647 | 646 | [
"DDInter11",
"DDInter383"
] | Acarbose | Cinoxacin | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Moderate | 1 | [
[
[
1647,
24,
646
]
],
[
[
1647,
21,
28722
],
[
28722,
60,
646
]
],
[
[
1647,
24,
322
],
[
322,
23,
646
]
],
[
[
1647,
23,
135
],
[
135,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cinoxacin"
]
],
[
[
"Acarbose",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (... | Acarbose (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Cinoxacin (Compound)
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Acarbose m... |
DB00277 | DB00475 | 1,031 | 1,119 | [
"DDInter1791",
"DDInter355"
] | Theophylline | Chlordiazepoxide | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. | Minor | 0 | [
[
[
1031,
23,
1119
]
],
[
[
1031,
23,
686
],
[
686,
40,
1119
]
],
[
[
1031,
62,
905
],
[
905,
40,
1119
]
],
[
[
1031,
62,
1174
],
[
1174,
... | [
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chlordiazepoxide"
]
],
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oxazepam"
],
... | Theophylline may cause a minor interaction that can limit clinical effects when taken with Oxazepam and Oxazepam (Compound) resembles Chlordiazepoxide (Compound)
Theophylline may cause a minor interaction that can limit clinical effects when taken with Lorazepam and Lorazepam (Compound) resembles Chlordiazepoxide (Comp... |
DB00938 | DB13928 | 455 | 1,385 | [
"DDInter1635",
"DDInter1660"
] | Salmeterol | Semaglutide | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
455,
24,
1385
]
],
[
[
455,
24,
1154
],
[
1154,
24,
1385
]
],
[
[
455,
24,
1399
],
[
1399,
63,
1385
]
],
[
[
455,
63,
839
],
[
839,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate ... |
DB00376 | DB04843 | 1,105 | 1,511 | [
"DDInter1870",
"DDInter1149"
] | Trihexyphenidyl | Mepenzolate | Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is n... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
1105,
24,
1511
]
],
[
[
1105,
24,
537
],
[
537,
24,
1511
]
],
[
[
1105,
35,
1192
],
[
1192,
24,
1511
]
],
[
[
1105,
63,
352
],
[
352,
... | [
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]... | Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Trihexyphenidyl (Compound) resembles Glycopyrronium (Compound) and Trihexyphenidyl may cause a moderate inte... |
DB01019 | DB01176 | 427 | 537 | [
"DDInter199",
"DDInter453"
] | Bethanechol | Cyclizine | Bethanechol is a synthetic ester that was initially synthesized in 1935.[A232905,L32539] As a cholinergic agent, bethanechol is similar in structure and pharmacological function to acetylcholine and is used in specific cases when stimulation of the parasympathetic nervous system is necessary.[A232905,L32539] For exampl... | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
427,
24,
537
]
],
[
[
427,
24,
1511
],
[
1511,
63,
537
]
],
[
[
427,
21,
28841
],
[
28841,
60,
537
]
],
[
[
427,
63,
1123
],
[
1123,
... | [
[
[
"Bethanechol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Bethanechol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
... | Bethanechol may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Bethanechol (Compound) causes Bronchospasm (Side Effect) and Bronchospasm (Side Effect) is caused by Cyclizine... |
DB01128 | DB05316 | 918 | 749 | [
"DDInter204",
"DDInter1467"
] | Bicalutamide | Pimavanserin | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Moderate | 1 | [
[
[
918,
24,
749
]
],
[
[
918,
62,
112
],
[
112,
23,
749
]
],
[
[
918,
24,
1264
],
[
1264,
24,
749
]
],
[
[
918,
63,
888
],
[
888,
2... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimavanserin"
]
],
[
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pimavanserin
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and D... |
DB00204 | DB00342 | 228 | 1,181 | [
"DDInter580",
"DDInter1770"
] | Dofetilide | Terfenadine | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Major | 2 | [
[
[
228,
25,
1181
]
],
[
[
228,
23,
112
],
[
112,
62,
1181
]
],
[
[
228,
24,
159
],
[
159,
63,
1181
]
],
[
[
228,
25,
1520
],
[
1520,
... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
]
],
[
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Dofetilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Terfenadine
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and ... |
DB01254 | DB01394 | 1,213 | 1,554 | [
"DDInter484",
"DDInter431"
] | Dasatinib | Colchicine | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Moderate | 1 | [
[
[
1213,
24,
1554
]
],
[
[
1213,
6,
4973
],
[
4973,
45,
1554
]
],
[
[
1213,
7,
2023
],
[
2023,
46,
1554
]
],
[
[
1213,
18,
16974
],
[
169... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colchicine"
]
],
[
[
"Dasatinib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Dasatinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Colchicine (Compound)
Dasatinib (Compound) upregulates RAP1GAP (Gene) and RAP1GAP (Gene) is upregulated by Colchicine (Compound)
Dasatinib (Compound) downregulates TUBB6 (Gene) and TUBB6 (Gene) is upregulated by Colchicine (Compound)
Dasatinib (Compou... |
DB09389 | DB12500 | 517 | 283 | [
"DDInter1315",
"DDInter714"
] | Norgestrel | Fedratinib | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
517,
24,
283
]
],
[
[
517,
63,
761
],
[
761,
24,
283
]
],
[
[
517,
64,
1101
],
[
1101,
24,
283
]
],
[
[
517,
24,
159
],
[
159,
6... | [
[
[
"Norgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Norgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
... | Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Norgestrel may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may caus... |
DB00197 | DB00841 | 1,324 | 532 | [
"DDInter1881",
"DDInter577"
] | Troglitazone | Dobutamine | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery. | Moderate | 1 | [
[
[
1324,
24,
532
]
],
[
[
1324,
24,
817
],
[
817,
40,
532
]
],
[
[
1324,
24,
473
],
[
473,
63,
532
]
],
[
[
1324,
63,
73
],
[
73,
2... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dobutamine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
],
[
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine (Compound) resembles Dobutamine (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that cou... |
DB00388 | DB00912 | 1,636 | 473 | [
"DDInter1453",
"DDInter1581"
] | Phenylephrine | Repaglinide | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
1636,
24,
473
]
],
[
[
1636,
21,
30513
],
[
30513,
60,
473
]
],
[
[
1636,
25,
551
],
[
551,
24,
473
]
],
[
[
1636,
63,
73
],
[
73,
... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Phenylephrine",
"{u} (Compound) causes {v} (Side Effect)",
"Ischaemia"
],
[
"Ischaemia",
"{u} (Side Effect) ... | Phenylephrine (Compound) causes Ischaemia (Side Effect) and Ischaemia (Side Effect) is caused by Repaglinide (Compound)
Phenylephrine may lead to a major life threatening interaction when taken with Phenelzine and Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Phe... |
DB01265 | DB06704 | 1,477 | 247 | [
"DDInter1757",
"DDInter952"
] | Telbivudine | Iobenguane (I-131) | Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects. | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Moderate | 1 | [
[
[
1477,
24,
247
]
],
[
[
1477,
21,
28787
],
[
28787,
60,
247
]
],
[
[
1477,
40,
139
],
[
139,
24,
247
]
],
[
[
1477,
21,
28787
],
[
2878... | [
[
[
"Telbivudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iobenguane"
]
],
[
[
"Telbivudine",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is ... | Telbivudine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane
Telbivudine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iobenguane (Compound)
Telbivudine (Compound) resembles Zidovudine (Compound) and Zidovudine may cause a moderate interac... |
DB01035 | DB04865 | 1,401 | 4 | [
"DDInter1524",
"DDInter1335"
] | Procainamide | Omacetaxine mepesuccinate | A derivative of procaine with less CNS action. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
1401,
24,
4
]
],
[
[
1401,
24,
770
],
[
770,
24,
4
]
],
[
[
1401,
64,
485
],
[
485,
24,
4
]
],
[
[
1401,
25,
1250
],
[
1250,
63,... | [
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidom... | Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Procainamide may lead to a major life threatening interaction when taken with Pentamidine and... |
DB00543 | DB01259 | 87 | 392 | [
"DDInter82",
"DDInter1024"
] | Amoxapine | Lapatinib | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
87,
24,
392
]
],
[
[
87,
21,
28852
],
[
28852,
60,
392
]
],
[
[
87,
23,
112
],
[
112,
23,
392
]
],
[
[
87,
24,
918
],
[
918,
24,... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Amoxapine",
"{u} (Compound) causes {v} (Side Effect)",
"Leukopenia"
],
[
"Leukopenia",
"{u} (Side Effect) is cause... | Amoxapine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Lapatinib (Compound)
Amoxapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lapati... |
DB01098 | DB06210 | 14 | 72 | [
"DDInter1622",
"DDInter631"
] | Rosuvastatin | Eltrombopag | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Moderate | 1 | [
[
[
14,
24,
72
]
],
[
[
14,
6,
15333
],
[
15333,
45,
72
]
],
[
[
14,
24,
384
],
[
384,
63,
72
]
],
[
[
14,
63,
467
],
[
467,
24,
... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Rosuvastatin",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B1"
],
[
"SLCO1B1",
"{u} (Gene) is bound by {v} (Comp... | Rosuvastatin (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Eltrombopag (Compound)
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Rosuvastat... |
DB00683 | DB01259 | 1,382 | 392 | [
"DDInter1212",
"DDInter1024"
] | Midazolam | Lapatinib | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
1382,
24,
392
]
],
[
[
1382,
6,
4973
],
[
4973,
45,
392
]
],
[
[
1382,
21,
28883
],
[
28883,
60,
392
]
],
[
[
1382,
63,
723
],
[
723,
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Midazolam",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Midazolam (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Midazolam (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Lapatinib (Compound)
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Apr... |
DB00748 | DB01114 | 662 | 272 | [
"DDInter297",
"DDInter362"
] | Carbinoxamine | Chlorpheniramine | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
662,
35,
272
]
],
[
[
662,
35,
358
],
[
358,
63,
272
]
],
[
[
662,
1,
11775
],
[
11775,
40,
272
]
],
[
[
662,
1,
11244
],
[
11244,
... | [
[
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate... | Carbinoxamine (Compound) resembles Chlorpheniramine (Compound) and
Carbinoxamine (Compound) resembles Orphenadrine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases wh... |
DB00095 | DB11834 | 66 | 1,303 | [
"DDInter623",
"DDInter849"
] | Efalizumab | Guselkumab | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Moderate | 1 | [
[
[
66,
24,
1303
]
],
[
[
66,
23,
1193
],
[
1193,
23,
1303
]
],
[
[
66,
24,
949
],
[
949,
24,
1303
]
],
[
[
66,
63,
58
],
[
58,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
... | Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Guselkumab
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetan... |
DB00658 | DB01208 | 965 | 945 | [
"DDInter1663",
"DDInter1705"
] | Sevelamer | Sparfloxacin | Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel. | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Moderate | 1 | [
[
[
965,
24,
945
]
],
[
[
965,
24,
739
],
[
739,
1,
945
]
],
[
[
965,
63,
1176
],
[
1176,
1,
945
]
],
[
[
965,
21,
28787
],
[
28787,
... | [
[
[
"Sevelamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Sevelamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
... | Sevelamer may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Sevelamer may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin (... |
DB00280 | DB09098 | 494 | 98 | [
"DDInter575",
"DDInter1700"
] | Disopyramide | Somatrem | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
494,
24,
98
]
],
[
[
494,
24,
608
],
[
608,
23,
98
]
],
[
[
494,
24,
159
],
[
159,
63,
98
]
],
[
[
494,
25,
11
],
[
11,
24,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larot... |
DB00574 | DB01149 | 121 | 851 | [
"DDInter717",
"DDInter1274"
] | Fenfluramine | Nefazodone | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Major | 2 | [
[
[
121,
25,
851
]
],
[
[
121,
24,
673
],
[
673,
40,
851
]
],
[
[
121,
25,
827
],
[
827,
40,
851
]
],
[
[
121,
24,
1374
],
[
1374,
6... | [
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nefazodone"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
],
[
"Arip... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole (Compound) resembles Nefazodone (Compound)
Fenfluramine may lead to a major life threatening interaction when taken with Trazodone and Trazodone (Compound) resembles Nefazodone (Compound)
Fenfluram... |
DB00397 | DB00414 | 1,466 | 590 | [
"DDInter1458",
"DDInter16"
] | Phenylpropanolamine | Acetohexamide | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Moderate | 1 | [
[
[
1466,
24,
590
]
],
[
[
1466,
24,
1551
],
[
1551,
62,
590
]
],
[
[
1466,
24,
1163
],
[
1163,
63,
590
]
],
[
[
1466,
64,
1230
],
[
1230,... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl... | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa and Methyldopa may cause a minor interaction that can limit clinical effects when taken with Acetohexamide
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Ra... |
DB09065 | DB14840 | 760 | 861 | [
"DDInter424",
"DDInter1601"
] | Cobicistat | Ripretinib | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Major | 2 | [
[
[
760,
25,
861
]
],
[
[
760,
25,
351
],
[
351,
24,
861
]
],
[
[
760,
64,
392
],
[
392,
24,
861
]
],
[
[
760,
63,
888
],
[
888,
24,... | [
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ripretinib"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} m... | Cobicistat may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Cobicistat may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate intera... |
DB00092 | DB01174 | 58 | 697 | [
"DDInter40",
"DDInter1442"
] | Alefacept | Phenobarbital | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
58,
24,
697
]
],
[
[
58,
24,
759
],
[
759,
1,
697
]
],
[
[
58,
24,
37
],
[
37,
62,
697
]
],
[
[
58,
24,
450
],
[
450,
23,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a minor interaction that can limit c... |
DB00619 | DB00909 | 1,419 | 306 | [
"DDInter909",
"DDInter1971"
] | Imatinib | Zonisamide | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Moderate | 1 | [
[
[
1419,
24,
306
]
],
[
[
1419,
6,
8374
],
[
8374,
45,
306
]
],
[
[
1419,
21,
28691
],
[
28691,
60,
306
]
],
[
[
1419,
24,
159
],
[
159,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zonisamide"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Imatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zonisamide (Compound)
Imatinib (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Zonisamide (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larot... |
DB00490 | DB01176 | 946 | 537 | [
"DDInter254",
"DDInter453"
] | Buspirone | Cyclizine | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
946,
24,
537
]
],
[
[
946,
63,
1242
],
[
1242,
24,
537
]
],
[
[
946,
24,
104
],
[
104,
1,
537
]
],
[
[
946,
21,
28930
],
[
28930,
... | [
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
... | Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdil... |
DB08865 | DB08932 | 1,593 | 1,398 | [
"DDInter448",
"DDInter1111"
] | Crizotinib | Macitentan | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity. | Moderate | 1 | [
[
[
1593,
24,
1398
]
],
[
[
1593,
6,
8374
],
[
8374,
45,
1398
]
],
[
[
1593,
21,
29429
],
[
29429,
60,
1398
]
],
[
[
1593,
23,
283
],
[
28... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macitentan"
]
],
[
[
"Crizotinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Crizotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Macitentan (Compound)
Crizotinib (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Macitentan (Compound)
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Fedratini... |
DB00209 | DB01409 | 352 | 1,415 | [
"DDInter1886",
"DDInter1815"
] | Trospium | Tiotropium | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L... | Moderate | 1 | [
[
[
352,
24,
1415
]
],
[
[
352,
6,
4304
],
[
4304,
45,
1415
]
],
[
[
352,
21,
29187
],
[
29187,
60,
1415
]
],
[
[
352,
24,
752
],
[
752,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Trospium",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)",
... | Trospium (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Tiotropium (Compound)
Trospium (Compound) causes Rhinitis (Side Effect) and Rhinitis (Side Effect) is caused by Tiotropium (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may... |
DB00543 | DB01128 | 87 | 918 | [
"DDInter82",
"DDInter204"
] | Amoxapine | Bicalutamide | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Moderate | 1 | [
[
[
87,
24,
918
]
],
[
[
87,
24,
129
],
[
129,
40,
918
]
],
[
[
87,
6,
12523
],
[
12523,
45,
918
]
],
[
[
87,
21,
28642
],
[
28642,
... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
... | Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Amoxapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Bicalutamide (Compound)
Amoxapine (Compound) causes Shock (Side Effect) and Shock (S... |
DB01155 | DB08875 | 872 | 1,618 | [
"DDInter813",
"DDInter262"
] | Gemifloxacin | Cabozantinib | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
872,
25,
1618
]
],
[
[
872,
62,
112
],
[
112,
23,
1618
]
],
[
[
872,
63,
480
],
[
480,
24,
1618
]
],
[
[
872,
24,
170
],
[
170,
... | [
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Met... | Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol an... |
DB00163 | DB00694 | 1,461 | 51 | [
"DDInter1943",
"DDInter485"
] | Vitamin E | Daunorubicin | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Moderate | 1 | [
[
[
1461,
24,
51
]
],
[
[
1461,
6,
5998
],
[
5998,
57,
51
]
],
[
[
1461,
24,
134
],
[
134,
24,
51
]
],
[
[
1461,
24,
1001
],
[
1001,
... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Vitamin E",
"{u} (Compound) binds {v} (Gene)",
"HMOX1"
],
[
"HMOX1",
"{u} (Gene) is downregulated by {v} (Compo... | Vitamin E (Compound) binds HMOX1 (Gene) and HMOX1 (Gene) is downregulated by Daunorubicin (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Vitamin ... |
DB00305 | DB01042 | 377 | 1,307 | [
"DDInter1232",
"DDInter1144"
] | Mitomycin | Melphalan | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Moderate | 1 | [
[
[
377,
24,
1307
]
],
[
[
377,
7,
3151
],
[
3151,
46,
1307
]
],
[
[
377,
54,
19138
],
[
19138,
15,
1307
]
],
[
[
377,
21,
29355
],
[
2935... | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Mitomycin",
"{u} (Compound) upregulates {v} (Gene)",
"DDB2"
],
[
"DDB2",
"{u} (Gene) is upregulated by {v} (Compou... | Mitomycin (Compound) upregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Melphalan (Compound)
Mitomycin (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Melphalan (Compound)
Mitomycin (Compound) causes Injection site reaction (Side Effect) ... |
DB00047 | DB00761 | 176 | 1,621 | [
"DDInter932",
"DDInter1497"
] | Insulin glargine | Potassium chloride | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Minor | 0 | [
[
[
176,
23,
1621
]
],
[
[
176,
24,
914
],
[
914,
63,
1621
]
],
[
[
176,
24,
743
],
[
743,
25,
1621
]
],
[
[
176,
24,
1414
],
[
1414,
... | [
[
[
"Insulin glargine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Potassium chloride"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diflunisa... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Potassium chloride
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with L... |
DB00804 | DB00985 | 1,507 | 1,443 | [
"DDInter543",
"DDInter562"
] | Dicyclomine | Dimenhydrinate | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyl... | Moderate | 1 | [
[
[
1507,
24,
1443
]
],
[
[
1507,
24,
1376
],
[
1376,
63,
1443
]
],
[
[
1507,
63,
357
],
[
357,
1,
1443
]
],
[
[
1507,
24,
358
],
[
358,
... | [
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimenhydrinate"
]
],
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
... | Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dimenhydrinate
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Benza... |
DB01021 | DB06335 | 674 | 761 | [
"DDInter1861",
"DDInter1646"
] | Trichlormethiazide | Saxagliptin | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
674,
24,
761
]
],
[
[
674,
1,
1577
],
[
1577,
24,
761
]
],
[
[
674,
40,
178
],
[
178,
24,
761
]
],
[
[
674,
63,
1573
],
[
1573,
... | [
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Trichlormethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide... | Trichlormethiazide (Compound) resembles Hydroflumethiazide (Compound) and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Trichlormethiazide (Compound) resembles Polythiazide (Compound) and Polythiazide may cause a moderate interaction that could exacerbate... |
DB00681 | DB01110 | 1,287 | 86 | [
"DDInter85",
"DDInter1209"
] | Amphotericin B | Miconazole | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Minor | 0 | [
[
[
1287,
23,
86
]
],
[
[
1287,
21,
29081
],
[
29081,
60,
86
]
],
[
[
1287,
25,
540
],
[
540,
63,
86
]
],
[
[
1287,
62,
1622
],
[
1622,
... | [
[
[
"Amphotericin B",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Miconazole"
]
],
[
[
"Amphotericin B",
"{u} (Compound) causes {v} (Side Effect)",
"Angioedema"
],
[
"Angioedema",
"{u} (Side Effect)... | Amphotericin B (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Miconazole (Compound)
Amphotericin B may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Miconazole... |
DB00374 | DB01166 | 1,061 | 477 | [
"DDInter1852",
"DDInter379"
] | Treprostinil | Cilostazol | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
1061,
24,
477
]
],
[
[
1061,
18,
4450
],
[
4450,
46,
477
]
],
[
[
1061,
7,
5727
],
[
5727,
46,
477
]
],
[
[
1061,
18,
12701
],
[
12701... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Treprostinil",
"{u} (Compound) downregulates {v} (Gene)",
"RRP8"
],
[
"RRP8",
"{u} (Gene) is upregulated by {v... | Treprostinil (Compound) downregulates RRP8 (Gene) and RRP8 (Gene) is upregulated by Cilostazol (Compound)
Treprostinil (Compound) upregulates AGR2 (Gene) and AGR2 (Gene) is upregulated by Cilostazol (Compound)
Treprostinil (Compound) downregulates MCUR1 (Gene) and MCUR1 (Gene) is downregulated by Cilostazol (Compound)
... |
DB00063 | DB14276 | 366 | 1,631 | [
"DDInter659",
"DDInter1892"
] | Eptifibatide | Turmeric | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
366,
23,
1631
]
],
[
[
366,
64,
20
],
[
20,
23,
1631
]
],
[
[
366,
25,
1018
],
[
1018,
23,
1631
]
],
[
[
366,
24,
1479
],
[
1479,
... | [
[
[
"Eptifibatide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenectep... | Eptifibatide may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Eptifibatide may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine may cause a minor i... |
DB00197 | DB00230 | 1,324 | 784 | [
"DDInter1881",
"DDInter1516"
] | Troglitazone | Pregabalin | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evide... | Moderate | 1 | [
[
[
1324,
24,
784
]
],
[
[
1324,
24,
222
],
[
222,
63,
784
]
],
[
[
1324,
24,
222
],
[
222,
21,
29785
],
[
29785,
60,
784
]
],
[
[
1324,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pregabalin"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Pregabalin
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and... |
DB01211 | DB09104 | 609 | 286 | [
"DDInter393",
"DDInter1118"
] | Clarithromycin | Magnesium hydroxide | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
609,
24,
286
]
],
[
[
609,
24,
481
],
[
481,
23,
286
]
],
[
[
609,
63,
1119
],
[
1119,
23,
286
]
],
[
[
609,
62,
752
],
[
752,
2... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Chlordiaze... |
DB00377 | DB11730 | 1,494 | 351 | [
"DDInter1382",
"DDInter1588"
] | Palonosetron | Ribociclib | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1494,
25,
351
]
],
[
[
1494,
23,
1247
],
[
1247,
23,
351
]
],
[
[
1494,
25,
222
],
[
222,
23,
351
]
],
[
[
1494,
24,
479
],
[
479,
... | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Palonosetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Su... | Palonosetron may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Palonosetron may lead to a major life threatening interaction when taken with Sibutramine and Sibutram... |
DB01006 | DB08820 | 300 | 1,478 | [
"DDInter1040",
"DDInter997"
] | Letrozole | Ivacaftor | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
300,
24,
1478
]
],
[
[
300,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
300,
21,
29221
],
[
29221,
60,
1478
]
],
[
[
300,
62,
307
],
[
307,
... | [
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Letrozole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Letrozole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Letrozole (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Ivacaftor (Compound)
Letrozole may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafini... |
DB00046 | DB08912 | 1,179 | 1,040 | [
"DDInter940",
"DDInter462"
] | Insulin lispro | Dabrafenib | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1179,
24,
1040
]
],
[
[
1179,
24,
168
],
[
168,
23,
1040
]
],
[
[
1179,
24,
870
],
[
870,
24,
1040
]
],
[
[
1179,
24,
192
],
[
192,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone... |
DB00009 | DB01404 | 1,271 | 757 | [
"DDInter56",
"DDInter820"
] | Alteplase | Ginseng | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Moderate | 1 | [
[
[
1271,
24,
757
]
],
[
[
1271,
24,
578
],
[
578,
63,
757
]
],
[
[
1271,
25,
553
],
[
553,
24,
757
]
],
[
[
1271,
25,
256
],
[
256,
... | [
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"... | Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Alteplase may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may cause a... |
DB00497 | DB01168 | 828 | 1,053 | [
"DDInter1366",
"DDInter1526"
] | Oxycodone | Procarbazine | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
828,
25,
1053
]
],
[
[
828,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
828,
24,
100
],
[
100,
24,
1053
]
],
[
[
828,
24,
830
],
[
830,
... | [
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Oxycodone",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compou... | Oxycodone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00238 | DB04868 | 188 | 478 | [
"DDInter1285",
"DDInter1293"
] | Nevirapine | Nilotinib | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
188,
24,
478
]
],
[
[
188,
24,
1468
],
[
1468,
63,
478
]
],
[
[
188,
6,
6017
],
[
6017,
45,
478
]
],
[
[
188,
21,
28762
],
[
28762,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Nevirapine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Nevirapine (Compound) ... |
DB00438 | DB01082 | 149 | 1,448 | [
"DDInter330",
"DDInter1713"
] | Ceftazidime | Streptomycin | Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of esse... | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Moderate | 1 | [
[
[
149,
24,
1448
]
],
[
[
149,
6,
10612
],
[
10612,
45,
1448
]
],
[
[
149,
21,
29327
],
[
29327,
60,
1448
]
],
[
[
149,
40,
1682
],
[
168... | [
[
[
"Ceftazidime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Ceftazidime",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compo... | Ceftazidime (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Streptomycin (Compound)
Ceftazidime (Compound) causes Renal failure (Side Effect) and Renal failure (Side Effect) is caused by Streptomycin (Compound)
Ceftazidime (Compound) resembles Ceftaroline fosamil (Compound) and Ceftaroline fosamil may ca... |
DB06176 | DB09083 | 1,342 | 880 | [
"DDInter1616",
"DDInter996"
] | Romidepsin | Ivabradine | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
1342,
25,
880
]
],
[
[
1342,
63,
480
],
[
480,
24,
880
]
],
[
[
1342,
24,
1478
],
[
1478,
24,
880
]
],
[
[
1342,
24,
159
],
[
159,
... | [
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol... | Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaft... |
DB00381 | DB00486 | 376 | 1,614 | [
"DDInter79",
"DDInter1253"
] | Amlodipine | Nabilone | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
376,
24,
1614
]
],
[
[
376,
24,
530
],
[
530,
1,
1614
]
],
[
[
376,
21,
28789
],
[
28789,
60,
1614
]
],
[
[
376,
63,
999
],
[
999,
... | [
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
... | Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Amlodipine (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Nabilone (Compound)
Amlodipine may cause a m... |
DB00108 | DB00188 | 1,066 | 168 | [
"DDInter1268",
"DDInter222"
] | Natalizumab | Bortezomib | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Major | 2 | [
[
[
1066,
25,
168
]
],
[
[
1066,
25,
1307
],
[
1307,
62,
168
]
],
[
[
1066,
64,
58
],
[
58,
24,
168
]
],
[
[
1066,
25,
1613
],
[
1613,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Melphalan"
],
[
"Melphalan",
"{u} m... | Natalizumab may lead to a major life threatening interaction when taken with Melphalan and Melphalan may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Natalizumab may lead to a major life threatening interaction when taken with Alefacept and Alefacept may cause a moderate interact... |
DB00902 | DB01224 | 104 | 623 | [
"DDInter1168",
"DDInter1553"
] | Methdilazine | Quetiapine | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Moderate | 1 | [
[
[
104,
35,
623
]
],
[
[
104,
63,
827
],
[
827,
1,
623
]
],
[
[
104,
1,
332
],
[
332,
1,
623
]
],
[
[
104,
40,
11237
],
[
11237,
1,... | [
[
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when tak... | Methdilazine (Compound) resembles Quetiapine (Compound) and
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Methdilazine (Compound) resembles Fluphenazine (Compound) and Fluphenazine (Compound) resembles Quet... |
DB00418 | DB08901 | 536 | 1,468 | [
"DDInter1650",
"DDInter1492"
] | Secobarbital | Ponatinib | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
536,
24,
1468
]
],
[
[
536,
24,
478
],
[
478,
24,
1468
]
],
[
[
536,
6,
3486
],
[
3486,
45,
1468
]
],
[
[
536,
21,
28722
],
[
28722,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Secobarbital (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ponatinib (Compound)
Secobarbital (Comp... |
DB00330 | DB08889 | 238 | 350 | [
"DDInter689",
"DDInter299"
] | Ethambutol | Carfilzomib | Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of _Mycob... | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
238,
24,
350
]
],
[
[
238,
21,
28762
],
[
28762,
60,
350
]
],
[
[
238,
24,
482
],
[
482,
24,
350
]
],
[
[
238,
63,
1451
],
[
1451,
... | [
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Ethambutol",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is cause... | Ethambutol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Carfilzomib (Compound)
Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Carfilzo... |
DB01115 | DB14724 | 336 | 48 | [
"DDInter1291",
"DDInter634"
] | Nifedipine | Emapalumab | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority... | Moderate | 1 | [
[
[
336,
24,
48
]
],
[
[
336,
40,
376
],
[
376,
24,
48
]
],
[
[
336,
25,
1456
],
[
1456,
24,
48
]
],
[
[
336,
24,
1409
],
[
1409,
24... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Nifedipine",
"{u} (Compound) resembles {v} (Compound)",
"Amlodipine"
],
[
"Amlodipine",
"{u} may cause a moderat... | Nifedipine (Compound) resembles Amlodipine (Compound) and Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Nifedipine may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate dis... |
DB04911 | DB08816 | 968 | 578 | [
"DDInter1347",
"DDInter1802"
] | Oritavancin | Ticagrelor | Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
968,
24,
578
]
],
[
[
968,
21,
28646
],
[
28646,
60,
578
]
],
[
[
968,
24,
868
],
[
868,
63,
578
]
],
[
[
968,
63,
79
],
[
79,
2... | [
[
[
"Oritavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Oritavancin",
"{u} (Compound) causes {v} (Side Effect)",
"Unspecified disorder of skin and subcutaneous tissue"
],
[
... | Oritavancin (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Oritavancin may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafen... |
DB00372 | DB00594 | 999 | 863 | [
"DDInter1793",
"DDInter68"
] | Thiethylperazine | Amiloride | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions... | Moderate | 1 | [
[
[
999,
24,
863
]
],
[
[
999,
63,
1648
],
[
1648,
24,
863
]
],
[
[
999,
24,
1344
],
[
1344,
63,
863
]
],
[
[
999,
25,
593
],
[
593,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Canaglif... |
DB00282 | DB01268 | 641 | 1,151 | [
"DDInter1383",
"DDInter1731"
] | Pamidronic acid | Sunitinib | Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid]. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as [ibandronic acid], [zoledronic ... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
641,
24,
1151
]
],
[
[
641,
6,
7960
],
[
7960,
46,
1151
]
],
[
[
641,
21,
29662
],
[
29662,
60,
1151
]
],
[
[
641,
24,
1228
],
[
1228,... | [
[
[
"Pamidronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Pamidronic acid",
"{u} (Compound) binds {v} (Gene)",
"FDPS"
],
[
"FDPS",
"{u} (Gene) is upregulated by {v} (... | Pamidronic acid (Compound) binds FDPS (Gene) and FDPS (Gene) is upregulated by Sunitinib (Compound)
Pamidronic acid (Compound) causes Candida infection (Side Effect) and Candida infection (Side Effect) is caused by Sunitinib (Compound)
Pamidronic acid may cause a moderate interaction that could exacerbate diseases when... |
DB00106 | DB01142 | 618 | 1,264 | [
"DDInter4",
"DDInter593"
] | Abarelix | Doxepin | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
618,
24,
1264
]
],
[
[
618,
24,
401
],
[
401,
24,
1264
]
],
[
[
618,
23,
112
],
[
112,
23,
1264
]
],
[
[
618,
24,
847
],
[
847,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"... | Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronid... |
DB00241 | DB11978 | 288 | 124 | [
"DDInter257",
"DDInter822"
] | Butalbital | Glasdegib | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
288,
24,
124
]
],
[
[
288,
24,
1135
],
[
1135,
23,
124
]
],
[
[
288,
24,
466
],
[
466,
62,
124
]
],
[
[
288,
25,
475
],
[
475,
2... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutam... |
DB00738 | DB04948 | 485 | 1,084 | [
"DDInter1420",
"DDInter1083"
] | Pentamidine | Lofexidine | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
485,
24,
1084
]
],
[
[
485,
23,
112
],
[
112,
23,
1084
]
],
[
[
485,
63,
618
],
[
618,
24,
1084
]
],
[
[
485,
24,
774
],
[
774,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Pentamidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Pentamidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lofexidine
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abar... |
DB00745 | DB01131 | 307 | 1,243 | [
"DDInter1236",
"DDInter1531"
] | Modafinil | Proguanil | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. | Moderate | 1 | [
[
[
307,
24,
1243
]
],
[
[
307,
6,
8374
],
[
8374,
45,
1243
]
],
[
[
307,
21,
28658
],
[
28658,
60,
1243
]
],
[
[
307,
74,
126
],
[
126,
... | [
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Proguanil"
]
],
[
[
"Modafinil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Modafinil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Proguanil (Compound)
Modafinil (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Proguanil (Compound)
Modafinil (Compound) resembles Warfarin (Compound) and Modafinil may cause a moderate interaction that could exacerb... |
DB00279 | DB00286 | 1,152 | 380 | [
"DDInter1074",
"DDInter440"
] | Liothyronine | Conjugated estrogens (topical) | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Estrone sodium sulfate is a steroid sulfate and an organic sodium salt. It is functionally related to an estrone. | Moderate | 1 | [
[
[
1152,
24,
380
]
],
[
[
1152,
24,
890
],
[
890,
1,
380
]
],
[
[
1152,
24,
177
],
[
177,
40,
380
]
],
[
[
1152,
6,
12977
],
[
12977,
... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conjugated estrogens"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
... | Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Mestranol and Mestranol (Compound) resembles Conjugated estrogens (Compound)
Liothyronine may cause a moderate in... |
DB09049 | DB12332 | 1,135 | 1,619 | [
"DDInter1261",
"DDInter1626"
] | Naloxegol | Rucaparib | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Minor | 0 | [
[
[
1135,
23,
1619
]
],
[
[
1135,
62,
307
],
[
307,
23,
1619
]
],
[
[
1135,
64,
1419
],
[
1419,
24,
1619
]
],
[
[
1135,
62,
888
],
[
888,
... | [
[
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Mod... | Naloxegol may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Naloxegol may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate in... |
DB00067 | DB00261 | 317 | 702 | [
"DDInter1921",
"DDInter93"
] | Vasopressin | Anagrelide | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Major | 2 | [
[
[
317,
25,
702
]
],
[
[
317,
23,
112
],
[
112,
62,
702
]
],
[
[
317,
24,
659
],
[
659,
63,
702
]
],
[
[
317,
25,
1154
],
[
1154,
6... | [
[
[
"Vasopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Anagrelide
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vi... |
DB01023 | DB06791 | 409 | 1,446 | [
"DDInter716",
"DDInter1021"
] | Felodipine | Lanreotide | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Moderate | 1 | [
[
[
409,
24,
1446
]
],
[
[
409,
24,
1017
],
[
1017,
63,
1446
]
],
[
[
409,
63,
1324
],
[
1324,
24,
1446
]
],
[
[
409,
1,
1081
],
[
1081,
... | [
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
... | Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Trog... |
DB00682 | DB00744 | 126 | 1,288 | [
"DDInter1951",
"DDInter1962"
] | Warfarin | Zileuton | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, a... | Moderate | 1 | [
[
[
126,
24,
1288
]
],
[
[
126,
6,
8374
],
[
8374,
45,
1288
]
],
[
[
126,
7,
2384
],
[
2384,
46,
1288
]
],
[
[
126,
24,
1297
],
[
1297,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Warfarin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Warfarin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zileuton (Compound)
Warfarin (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Zileuton (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a m... |
DB00322 | DB01042 | 141 | 1,307 | [
"DDInter742",
"DDInter1144"
] | Floxuridine | Melphalan | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Moderate | 1 | [
[
[
141,
24,
1307
]
],
[
[
141,
7,
3151
],
[
3151,
46,
1307
]
],
[
[
141,
21,
28778
],
[
28778,
60,
1307
]
],
[
[
141,
23,
956
],
[
956,
... | [
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Floxuridine",
"{u} (Compound) upregulates {v} (Gene)",
"DDB2"
],
[
"DDB2",
"{u} (Gene) is upregulated by {v} (Co... | Floxuridine (Compound) upregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Melphalan (Compound)
Floxuridine (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Melphalan (Compound)
Floxuridine may cause a minor interaction that can limit clinical effects when taken... |
DB01142 | DB01232 | 1,264 | 1,327 | [
"DDInter593",
"DDInter1640"
] | Doxepin | Saquinavir | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Major | 2 | [
[
[
1264,
25,
1327
]
],
[
[
1264,
63,
915
],
[
915,
40,
1327
]
],
[
[
1264,
6,
10215
],
[
10215,
45,
1327
]
],
[
[
1264,
21,
28893
],
[
28... | [
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
],
[
"Atazanavir",
... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Saquinavir (Compound)
Doxepin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Saquinavir (Compound)
Doxepin (Compound) causes Hallucination (Side Effect) and Hallucinatio... |
DB00227 | DB12332 | 1,463 | 1,619 | [
"DDInter1098",
"DDInter1626"
] | Lovastatin | Rucaparib | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1463,
24,
1619
]
],
[
[
1463,
24,
112
],
[
112,
23,
1619
]
],
[
[
1463,
24,
259
],
[
259,
24,
1619
]
],
[
[
1463,
63,
58
],
[
58,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Ril... |
DB00820 | DB01234 | 402 | 1,220 | [
"DDInter1736",
"DDInter513"
] | Tadalafil | Dexamethasone | Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibito... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
402,
24,
1220
]
],
[
[
402,
6,
8374
],
[
8374,
45,
1220
]
],
[
[
402,
21,
29106
],
[
29106,
60,
1220
]
],
[
[
402,
63,
1101
],
[
1101,... | [
[
[
"Tadalafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Tadalafil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Tadalafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dexamethasone (Compound)
Tadalafil (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Dexamethasone (Compound)
Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexar... |
DB06204 | DB09268 | 768 | 1,662 | [
"DDInter1746",
"DDInter1464"
] | Tapentadol | Picosulfuric acid | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
768,
24,
1662
]
],
[
[
768,
64,
73
],
[
73,
24,
1662
]
],
[
[
768,
63,
820
],
[
820,
24,
1662
]
],
[
[
768,
24,
407
],
[
407,
63... | [
[
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Tapentadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phentermine"
],
[
"Ph... | Tapentadol may lead to a major life threatening interaction when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.